The University of Pittsburgh Cancer Institute (UPCI) Investigational Drug Service (IDS) is directed by Brian M. Miller, PharmD who is assisted by Elizabeth A. Paul, RPh and a pharmacy technician, Kristine M. Fischl. In addition, the clinic pharmacy that works in tandem with the IDS has three full-time pharmacy technicians, four full-time pharmacists, and two part-time pharmacists. These individuals also participate in treating patients enrolled in protocol treatments mainly through order-entry, mixing chemotherapy, and dispensing provided oral medication. The IDS oversees all pharmacy procedures and processes at the UPCI central and community clinical sites and the Clinical and Translational Research Center (CTRC) where UPCI sponsored studies are implemented and most Phase I studies take place. The IDS coordinate all pharmacy procedures associated with UPCI drug-related research protocols. The goal of the IDS is to ensure that the procurement, receipt, storage, accountability, preparation, dispensing, labeling, and shipping of investigational drugs are performed in accordance with all state and federal laws, Joint Commission on Accreditation of Healthcare Organizations (JCAHO), and the local IRB approved protocol guidelines. Clinical recommendations for drug therapy, monitoring plans for a regimen, managing adverse events, and dose calculations are made with respect to the treatment of patients. Additional responsibilities of the IDS include reviewing all approved IRB protocols, standard chemotherapy and protocol regimens, supportive care regimens (antiemetics and other premedications), and investigational drug policies and procedures. UPCI's Off-site locations require special efforts to ensure rigorous and successful implementation, coordination, and monitoring clinical protocols. Throughout the entire network of cancer sites, the IDS provides oversight and monitoring for all pharmacy related activities. IDS also implements a quality assurance program, which includes labeling drugs per protocol and placing specific labeling on each medication to ensure proper dispensing, and an education program of pharmacists and/or pharmacy technicians for new protocols and treatments, inventory control, and optimized patient care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705418
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$46,566
Indirect Cost
$15,761
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Du, Tian; Sikora, Matthew J; Levine, Kevin M et al. (2018) Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Res 20:106
Wang, Zehua; Yang, Bo; Zhang, Min et al. (2018) lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell 33:706-720.e9
Volonte, Daniela; Vyas, Avani R; Chen, Chen et al. (2018) Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. J Biol Chem 293:1794-1809
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Liu, Zhuqing; McMichael, Elizabeth L; Shayan, Gulidanna et al. (2018) Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res 24:4529-4538
Song, Xinxin; Zhu, Shan; Xie, Yangchun et al. (2018) JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. Gastroenterology 154:1480-1493
Santos, Patricia M; Butterfield, Lisa H (2018) Dendritic Cell-Based Cancer Vaccines. J Immunol 200:443-449
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Chartoumpekis, Dionysios V; Yagishita, Yoko; Fazzari, Marco et al. (2018) Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice. JCI Insight 3:

Showing the most recent 10 out of 1187 publications